Objective-To determine the role of Wnt antagonist Dickkopf (DKK) 1 in human endothelial colony-forming cells (ECFCs) in view of the emerging importance of Wnt pathways in vascular biology. Methods and Results-Endothelial progenitor cells have been proposed to be crucial in tumor neovascularization.
W ingless related proteins (Wnts) are powerful regulators of cell proliferation and differentiation, and their signaling pathway involves proteins that participate directly in both gene transcription and cell adhesion. 1 The major signaling pathway of Wnt is the canonical pathway that results from Wnt binding to the frizzled and low-densitylipoprotein-receptor-related protein (LRP) families on the cell surface. Complex formation induces ␤-catenin nuclear entry and forms a complex with transcription factor T cell factor (TCF) and/or lymphoid enhancer factor (LEF) to activate transcription of Wnt target genes. The Wnt pathway is modulated by several Wnt antagonists, including Dickkopfs (DKKs). 2 The DKK family encodes secreted proteins of 255 to 350 amino acids and comprises 4 main members in vertebrates (DKK1 to DKK4). DKK1, the most widely studied member of this family, has been implicated in various physiological and pathological processes in human adults. DKK1 mediates inflammation in atherosclerotic lesions 3 and mobilizes progenitor cells by activating the bone marrow endosteal stem cell niche. 4 Recently, serum levels of DKK1 correlated with the extent of bone disease in patients with multiple malignant neoplasms, such as breast cancer. 5 In tumoral angiogenesis, endothelial cells have distinct gene expression profiles when compared with normal endothelial cells. Notably, they express high levels of DKK3. 6, 7 However, the role of DKK1 in tumoral angiogenesis and postnatal vasculogenesis by endothelial progenitor cells (EPCs) has not yet been studied.
Bone marrow-derived cells have been shown to contribute to tumor neovasculature. 8, 9 The active cell population in bone marrow-derived cells has been proposed to be EPCs. 10 -13 EPCs are a crucial interface in tumor neovascularization and dissemination 14 and have been considered as a breast tumor biomarker. 15 At least 2 populations of EPCs have been described. 16 "Early" EPCs, also called "circulating angiogenic cells" (CACs), are spindle shaped and express both endothelial and leukocyte markers. "Late" EPCs, also called endothelial colony-forming cells (ECFCs), 11, 17 develop after 2 to 3 weeks of culture and have the characteristics of precursor cells committed to the endothelial lineage. CACs and ECFCs have therapeutic potential; however, in vivo, cells that merge into neovessels have an ECFC phenotype. 11, 12 To determine the potential of ECFCs as a cell therapy product and/or as an angiogenic cell type responsive of tumoral angiogenesis, a better understanding of the mechanisms underlying their angiogenic properties is needed.
Herein, we report that the Wnt canonical pathway antagonist DKK1 enhances the angiogenic properties of ECFCs. Because increased DKK1 levels are found in the serum of patients with breast cancer, 5 we suspected that DKK1 might correlate with breast tumor vascularization. We further investigated how DKK1 secreted from ECFCs, and from another proposed angiogenic cell type (mesenchymal stem cells [MSCs]), could interfere with cell angiogenic properties.
Methods
Experiments, including in vitro angiogenic assays, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and in vivo Matrigel plug, have been described elsewhere and in detail in supplemental files (available online at http://atvb.ahajournals.org).
A human breast carcinoma xenograft-12 (HBCx-12) was previously described. 18 HBCx-12 xenograft fragments of 30 mm 3 were subcutaneously grafted into the interscapular fat pad of 4-to 6-week-old female athymic nude mice (Janvier, Le Genest St Isle, France).
When the tumors reached a volume of approximately 200 mm 3 , animals were ranked according to the tumor volume and divided into 3 groups (6 animals per group) such that the mean and median of tumor volume of the 3 groups were closely matched. Treatment was started on day 1 and given over 3 weeks. Mice were injected twice a week peritumorally with recombinant mouse DKK1 at a dosage of 100 or 500 ng per animal or with PBS containing 0.1% bovine serum albumin as a vehicle control, in a total volume of 100 L.
The study was approved by the local ethics committee of Hôpital des Instructions et des Armées de Begin in France (registration number: 201008043234797), and the study protocol conformed to the ethical guidelines of the Declaration of Helsinki.
Results

Differential Expression of the Wnt Canonical Pathway in CACs and ECFCs
The starting material used to isolate endothelial populations consisted of mononuclear cells (MNCs) from either adult peripheral blood or human umbilical cord blood. On day 5, CAC colonies were identified as elongated sprouting cells that express leukocyte, monocyte, and endothelial markers (supplemental Figure I) . ECFCs have a cobblestone appearance typical of the endothelial lineage and express only endothelial markers (supplemental Figure I) . To identify the Wnt canonical pathway components expressed in human ECFCs and CACs, gene expression of LRP5, LRP6, and TCF/LEF transcription cofactors was quantified by RT-qPCR. Total RNA was isolated from adult peripheral blood and cord blood ECFCs between 30 and 40 days of culture and from CACs after 5 days of culture. LRP5/LRP6 were strongly expressed by ECFCs from both sources; they were 100-fold lower expressed by CACs (supplemental Figure II ). Because these genes encode Wnt coreceptors specific for the canonical pathway, this finding suggested that the ␤-catenin pathway is constitutively expressed in ECFCs but not in CACs. We confirmed the presence of ␤-catenin protein in ECFCs by Western blot and its absence from CACs (supplemental Figure II ). We detected ␤-catenin mRNA in CACs, at a level comparable to that found in total MNCs and whole blood (supplemental Figure III ) and significantly lower than that found in ECFCs from adult or cord blood. Moreover, we found strong expression of Wnt ligands and fizzled (FZD) receptors in CACs (supplemental Figure IV) , strongly suggesting that the Wnt pathway is expressed in CACs, even if ␤-catenin is not detected at the protein level. TCF/LEF gene expression also differed between the 2 types of EPC (supplemental Figure II ). Indeed, although TCF like 1 (TCFL1) and TCF like 2 (TCFL2) or TCF4 were strongly expressed in ECFCs, LEF1 and TCF7 were expressed at high levels in CACs but not in ECFCs.
Wnt Antagonist DKK1 Enhances Angiogenesis Mediated by ECFCs in Vitro
Based on our finding that the ␤-catenin pathway is present in ECFCs, and on recent data showing a role of Wnt signaling in endothelial commitment of embryonic stem cells, 19 we first investigated the effect of the Wnt canonical pathway antagonist DKK1 on the emergence of ECFC colonies. As shown in Figure 1A , adding DKK1 (human recombinant DKK1, R&D Systems, Lille, France) from the first week of culture did not modify the number of ECFC colonies obtained with MNCs from either cord or adult blood (Pϭ0.31 and Pϭ0.23, respectively). Moreover, DKK1 did not modify the length of this period (Pϭ0.22 for cord blood, and Pϭ0.92 for adult blood) ( Figure 1B ). We also observed a more important size of colonies observed at day 14 of culture (supplemental Figure V) .
We further studied the angiogenic implication of DKK1 in cord blood-derived ECFCs. Thus, to examine the effects of DKK1 on proliferation, ECFCs were treated with recombinant DKK1 for 72 hours. As shown in Figure 1C and 1D, 100 and 1000 ng/mL of DKK1 significantly promoted ECFC proliferation, which was measured with 2 different methods (para-nitrophenyl phosphate [pNPP] release in Figure 1C and Tritiated thymidine ([3H-TdR]) incorporation in Figure 1D ), with no dose effect between 100 and 1000 ng/mL. Lower doses, ranging between 1 and 10 ng/mL, had no proliferative effect on ECFCs (data not shown). To determine whether DKK1 is involved in progenitor proliferation or endothelial cell proliferation in general, we explored its effect on human umbilical vein endothelial cells and found that, in this mature cell type, DKK1 had no proliferative effects (supplemental Figure VI ). We used a Matrigel model (Beckton Dickinson, Franklin Lakes, NJ) to examine the capacity of DKK1-activated ECFCs to differentiate into capillary-like structures. Treatment with DKK1 induced a significant increase in ECFC organization into branched structures and pseudotubes with enclosed areas ( Figure 1F ). Overall, DKK1 did not modify the commitment of MNCs to ECFCs; instead, it stimulated their angiogenic properties in vitro.
CXCR4 and Vascular Endothelial Growth Factor Receptor 2 Pathway Blockade Inhibits ECFC Proliferation and Tube Formation Induced by DKK1 Activation
To decipher the specific role of DKK1 in ECFCs, we quantified DKK1-induced transcriptional modifications by real-time RT-qPCR. We focused on angiogenic factors, such as vascular endothelial growth factor (VEGF), angiopoietins, and stromal cell-derived factor-1 (SDF-1), and their receptors. No change in angiopoietin gene expression was observed. In contrast, we found that VEGF receptor 2 (VEGFR2), SDF-1, and chemokine (CXC motif) receptor 4 (CXCR4) were slightly increased after 8 and 12 hours; a strong increase was observed after 24 hours (supplemental Table) . CXCR4 and VEGFR2 protein expression, quantified by flow cytometry, was increased at 48 hours (supplemental Figure VII) . Given the role of DKK1 in VEGFR2 and CXCR4/SDF-1 gene expression, we examined the effect of anti-CXCR4 -and anti-VEGFR2-blocking antibodies on DKK1-induced proliferation and tubule morphogenesis. The proliferative effect of DKK1 was abrogated by anti-VEGFR2 but not by anti-CXCR4 ( Figure 1E ). Conversely, the DKK1induced increase in tube formation in Matrigel was blocked by anti-CXCR4 but not by anti-VEGFR2 ( Figure 1F 
Comparative DKK1, VEGFR2, and SDF-1 Pathway Gene Expression in Human Breast Tumors
To explore the role of DKK1 in breast tumor vascularization, we quantified the expression of DKK1, VEGFR2, CXCR4, and SDF-1 by real-time RT-qPCR and the degree of neovascularization, quantified by von Willebrand factor (vWF) expression, in a well-characterized series of 62 estrogen receptor ␣-positive human breast tumors. We found that DKK1 expression was increased in breast cancer tissue compared with normal breast tissue (data not shown) and that DKK1 correlated positively with vWF content and with VEGFR2 and SDF-1 transcript levels (Spearman rank correlation test, Table) .
The association between DKK1 expression and tumor vascularization was confirmed at the protein level by com-parative immunohistochemical analysis of tissue sections from human breast malignant tissues (nϭ5) and normal breast tissues (nϭ5). Vessels present in the tumor specimens and healthy breast tissues stained positive for CD31, whereas only tumor vessels stained positive for DKK1 (Figure 2A through 2D). Moreover, we quantified, by immunofluorescence analysis, the expression of CD31 (red, Figure 2E ) and DKK1 (green, Figure 2F ) and show a colocalization of CD31 and DKK1 in endothelial cells of human breast cancer (merge, supplemental Figure X ).
DKK1 Silencing in Cord Blood ECFCs Decreases Their Angiogenic Phenotype
EPCs are involved in cancer development and neovascularization, and the level of angiogenic activity in breast tumors is a prognostic factor. 20 Newly formed vessels that appear after treatment with bone marrow (BM)-MNCs in patients with critical leg ischemia have an ECFC phenotype, 12 confirming preclinical data from Yoder et al. 11 Herein, we found that ECFCs expressed DKK1 transcripts, contrary to CACs ( Figure 3A ). We then explored the effect of DKK1 gene inhibition by RNA interference on ECFC angiogenic potential. We verified that DKK1 mRNA expression remained strongly inhibited by the specific small and interfering RNA (siRNA) during the days after transfection ( Figure 3B ) and confirmed that siRNA induces a strong decrease in DKK1 levels in ECFC supernatants (Pϭ0.0002, Figure 3C ). We then explored the effect of DKK1 gene inhibition on the angiogenic properties of ECFCs in vivo. DKK1 inhibition resulted in decreased expression of SDF-1, CXCR4, and VEGFR2 ( Figure  3D ). These findings are in line with an autocrine effect of DKK1 on ECFCs, which partially reproduces the effect of exogenous DKK1. We then studied the effect of DKK1 inhibition on ECFC angiogenic properties and found that DKK1-siRNA induced a strong decrease in proliferation and pseudotube formation (Figure 3E and 3F ). Finally, we tested DKK1-inhibited ECFCs in a nude mouse model of hind limb ischemia and found a significant decrease of revascularization of DKK1-inhibited ECFCs compared with control ECFCs (PϽ0.05, Figure 3G ). 
Effect of DKK1 on Angiogenesis In Vivo
We used the Matrigel plug assay as a model of in vivo angiogenesis. Basic fibroblast growth factor-containing plugs, with and without DKK1 (100 or 1000 ng per plug, mouse recombinant DKK1, R&D Systems, Lille, France), were implanted subcutaneously in C57/B16J mice. The plugs were recovered 14 days later, and their blood vessel content was analyzed. DKK1 enhanced blood vessel formation in the plugs macroscopically ( Figure 4A and 4B) , as confirmed by measuring the hemoglobin content ( Figure 4C and supplemental Figure XI ) and the soluble VEGFR2 (sVEGFR2) content ( Figure 4D ). To confirm in a second model the implication of DKK1 in neovascularization, we used a model of breast cancer xenograft in nude mice. When the tumor reached a volume of approximately 200 mm 3 , mice were injected peritumorally with 100 or 500 ng of DKK1 every 3 days over 14 days. Tumor development was monitored every 3 to 4 days using a caliper. As shown in Figure 4E , a significant tumor growth increase was obtained by the administration of 100 ng per mouse (PϽ0.05). Similar results were obtained with 500 ng per animal (data not shown). Because these data suggested that neovascularization could have promoted tumor development, mice were euthanized at day 18 after the beginning of the treatment and tumors were collected for immunofluorescent assays. Anti-CD31 staining clearly revealed that xenografts treated with DKK1 displayed more blood vessels ( Figure 4F , right panel) than those injected only with the vehicle (Figure 4F , left panel).
DKK1 Silencing in Mesenchymal Stem Cells Decreases Their Angiogenic Potential
MSCs have been described in the tumor angiogenic process 21 and are a potential source of DKK1. 22 We used MSCs isolated from the bone marrow of patients with critical leg ischemia ( Figure 5A ) and inhibited DKK1 secretion by RNA interference (Figure 5B ). Decreased DKK1 expression was associated with a decrease in MSC proliferation ( Figure 5C ). The conditioned medium of MSCs transfected with DKK1-siRNA or control-siRNA was used to activate ECFCs. We found that MSC-conditioned medium from DKK1-siRNAtransfected MSCs had a smaller effect on ECFC proliferation ( Figure 5D ) and pseudotube formation ( Figure 5E ) compared with control siRNA-transfected MSCs. Finally, MSCs transfected with DKK1-siRNA had lower angiogenic potential in ischemic nude mice ( Figure 5F ). These results suggest that MSCs have angiogenic potential in vitro on ECFCs and in vivo, probably, at least in part, because of their secretion of DKK1.
Discussion
Recent studies 1, 19 have suggested an important role of Wnt signaling in vascular development and cancer. Herein, we show that the Wnt antagonist DKK1 is an angiogenic factor for ECFCs, which participate in neovessel formation in human and preclinical models of lower-limb ischemia. 11, 12 As a role of the Wnt canonical inhibitor, DKK1 has been implicated in malignant neoplasms, a situation in which neoangiogenesis is strongly enhanced; we chose to explore the function of DKK1 in ECFCs. Physiologically, DKK1 mobilizes progenitor cells from the bone marrow endosteal stem cell niche. 4 In breast cancer, the DKK1 expression level correlates with the rate of progression. 23 In atherosclerosis, DKK1 is overexpressed in plaque and enhances the inflammatory interaction between platelets and endothelial cells. 3 However, little is known about the role of DKK1 in adult angiogenesis mediated by ECFCs.
Aicher et al 4 showed that DKK1 suppresses canonical Wnt signaling in bone marrow endosteal cells, suggesting a regulatory role for DKK1 in the bone marrow stem cell niche. Intriguingly, DKK1 mobilized vasculogenic progenitor cells without concomitant release of inflammatory cells. 4 CACs are committed to the endothelial lineage but retain monocyte markers. These cells could be considered as inflammatory cells because they are mobilized in this context. 24 One possible explanation for the lack of mobilization could be inadequate LRP5/LRP6 levels and ␤-catenin pathway activity in inflammatory cells, as observed in CACs.
Wnt signaling modulates the stem cell niche and directly modulates stem cell proliferation, expansion, and differentiation. Moreover, Wnt was recently shown to induce embryonic stem cell commitment to the endothelial lineage. 19 Therefore, DKK1 might diminish, rather than enhance, ECFC proliferation. The observed stimulation of ECFC proliferation by DKK1 may be explained by the fact that DKK1 can only affect progenitor cells with active Wnt signaling. Indeed, our experiments involved homogeneous populations raised from single EPCs. These findings suggest that DKK1 might have the potential to enhance vasculogenic cell therapy approaches.
Herein, we show that DKK1 added to the plugs enhances vascularization in situ. In the experiments conducted by Aicher et al, 4 DKK1 systemically administered induced a mobilization of stem cells from the bone marrow niche into the plugs. One limitation of our study is the difficulty in demonstrating that Wnt signaling is blocked in the presence of DKK1 in the vessels within the Matrigel plugs in vivo. Moreover, we cannot exclude any effect of DKK1 on a wide variety of cells (eg, leukocytes, which may be recruited [or prevented from being recruited] into the Matrigel plugs). These cells might produce angiogenic factors and could directly affect local endothelium. However, we explored DKK1 effect on human umbilical vein endothelial cells and found that, in this mature cell type, DKK1 had no influence on proliferation.
DKK1 was recently reported to be involved in cardiovascular lineage commitment. 25 However, therapies based on DKK1 may result in increased mobilization of vasculogenic progenitor cells and, subsequently, in increased local neovascularization processes that might burst tumor progression. In atherosclerosis, a recent study 3 showed that platelets are an important source of DKK1 and that DKK1 influences platelet-mediated endothelial cell activation and atherosclerotic lesions. Given the importance of platelets as a source of both angiogenic factors, such as VEGF, and DKK1, modulation of platelet secretion might represent a further means of control-ling angiogenesis, especially during cancer. DKK1 blockade has recently been proposed as a therapeutic measure in multiple myeloma. 26 Our findings that DKK1 is involved in EPC-related neoangiogenesis and in breast tumor vascularization confirm DKK1 as a potential treatment target and also designate it as a potential new marker of proliferative or tumoral endothelium, in the same way as DKK3. 7 DKK1 serum levels are increased in breast cancer, 5 and ECFCs appear to contribute to tumor neovascularization and dissemination. 14 Herein, we show that DKK1 enhances the angiogenic potential of ECFCs. DKK1 could act in concert with proangiogenic growth factors produced by tumor cells themselves or with the inflammatory environment, thereby enhancing metastatic potential. We found a correlation between DKK1 expression and human breast tumor vascularity, quantified by vWF expression. Moreover, the DKK1 signaling pathway correlated with VEGFR2 and SDF-1 expression, as found in our in vitro cellular model of ECFCs. The lack of correlation between DKK1 and CXCR4 in these tumors suggests that a more complex mechanism operates in vivo, possibly involving endothelium-stroma-tumor interactions. One possibility is that CXCR4 is strongly expressed by breast cancer cells. 27 Finally, we showed the angiogenic effects of DKK1 secreted by other cells known to be indirectly involved in angiogenesis, such as MSCs. Because MSCs have been described in the tumor angiogenic process 21 and are a potential source of DKK1, 22 we inhibited DKK1 in MSCs and showed, such as previously described for another Wnt inhibitor (ie, frizzled-related protein-1 [FRP1]), 28,29 that secreted DKK1 had an angiogenic effect on ECFCs. Moreover, DKK1-inhibited MSCs had a smaller therapeutic angiogenic effect in vivo.
In conclusion, we present evidence that the Wnt inhibitor, DKK1, modulates ECFC angiogenic in vitro and in vivo properties. DKK1 could exert its effects via the VEGFR2 and SDF-1 signaling pathways. The positive correlation between DKK1 expression and vWF, VEGFR2, and SDF-1 expression in breast tumors suggests that dysregulated or DKK1-stimulated EPCs might play an important role in breast cancer and neovascularization. As a specific angiogenic growth factor, DKK1 might serve to optimize regenerative cell therapy and as a therapeutic target for inhibiting neovascularization.
